Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Protein-protein interaction inhibitors

Lookup NU author(s): Dr Ian HardcastleORCiD

Downloads

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Abstract

The study of cellular mechanisms of cancer growth and survival has revealed a complex web of signalling pathways that produce the ‘hallmarks of cancer’. A number of critical cellular signalling nodes have been characterised from which many new drug targets have been proposed. A number of these nodes are regulated by protein-protein interactions, and so present attractive, if challenging, targets for drug discovery. Drug discovery efforts towards three PPI families have resulted in clinically investigated drugs: i.e. Bcl-2 family inhibitors, MDM2-p53 inhibitors and IAP inhibitors. The discovery and optimisation of these drug classes are detailed in this chapter.

Publication metadata

Author(s): Hardcastle IR

Editor(s): Bernstein, PR; Georg, GI; Keller, Th; Kobayashi, T; Lowe, JA; Meanwell, NA; Saxena, AK; Stilz, U; Supuran, CT; Zhang, A

Publication type: Book Chapter

Publication status: Published

Book Title: Topics in Medicinal Chemistry

Year: 2017

Pages: 1-35

Online publication date: 25/07/2017

Acceptance date: 30/06/2017

Publisher: Springer

Place Published: Berlin, Heidelberg

URL: https://doi.org/10.1007/7355_2017_27

DOI: 10.1007/7355_2017_27

Share